CareDx (CDNA) vs Henry Schein (HSIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CareDx (CDNA) has outperformed Henry Schein (HSIC) over the past year, gaining 307.5% versus a gain of 13.8%. Over five years, CDNA leads with a +65.2% price change compared with +13.4% for HSIC. Henry Schein is the larger company by market cap ($9.23 billion vs $3.68 billion), about 2.5 times the size, while CareDx is growing revenue faster (+13.8% vs +4.0%).
On valuation, Henry Schein trades at a lower forward P/E (13.9x vs 44.7x for CareDx). Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -5.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | HSIC |
|---|---|---|
| Share price | $70.00 | $83.52 |
| Market cap | $3.68B | $9.23B |
| 1-day change | -2.67% | -1.51% |
| YTD return | +271.55% | +10.51% |
| 1-year return | +307.45% | +13.79% |
| 5-year return | +65.21% | +13.42% |
| P/E ratio (TTM) | 29.54 | 22.88 |
| Forward P/E | 44.75 | 13.91 |
| EPS (TTM) | $2.37 | $3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $379.81M | $13.18B |
| Revenue growth (YoY) | +13.79% | +4.03% |
| Net income (latest FY) | $-21.35M | $398.00M |
| Gross margin | — | 31.14% |
| Operating margin | -8.10% | 4.95% |
| Net margin | -5.62% | 3.02% |
| 52-week high | $90.87 | $92.18 |
| 52-week low | $15.56 | $68.70 |
| Distance from 52-week high | -22.97% | -9.39% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +34.90% | +15.98% |
| Average volume | 1.30M | 1.33M |
| Shares outstanding | 52.54M | 110.54M |
| Employees | 761 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Henry Schein is about 2.5 times larger than CareDx by market value ($9.23B vs $3.68B).
- CDNA has outperformed HSIC by 293.7 percentage points over the past year.
- CareDx trades at a higher earnings multiple (29.5x vs 22.9x trailing P/E).
- Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -5.6 cents for CareDx.
- CareDx grew revenue faster in its latest fiscal year (+13.79% vs +4.03%).
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
CDNA vs HSIC FAQ
Which is bigger, CareDx or Henry Schein?
Henry Schein (HSIC) is larger, with a market capitalization of $9.23B compared with $3.68B for CareDx (CDNA).
Which stock has performed better over the past year, CDNA or HSIC?
CDNA returned +307.45% over the past 12 months, compared with +13.79% for HSIC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CDNA or HSIC?
HSIC has the lower trailing P/E at 22.9, versus 29.5 for CDNA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are CareDx and Henry Schein in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.